As another fantastic year comes to a close, we extend our deepest gratitude to everyone who has played a role in our journey so far. In pursuing our ambitious goals and taking further steps forward, we acknowledge that none of this growth would have been possible without the trust and support of our customers and partners worldwide.

Thank you for being part of our story. Let’s reminisce on our best moments below!

1. Lunit X Capio S:t Göran Hospital (From Clinical Evidence to Actual AI Implementation)

Lunit will supply Lunit INSIGHT MMG, our AI solution for 2D mammography, to Capio S:t Göran Hospital, Sweden's largest private hospital, for the next three years.

This collaboration results from the world’s first prospective study, ScreenTrustCAD, published in the Lancet Digital Health.ScreenTrustCAD states that an AI solution can replace one human reader in the European double-reading system with a higher cancer detection rate and lower recall rate.

2. Lunit INSIGHT DBT - CE2797  EU MDR  & FDA 510(k) Cleared

Our AI solution for Digital Breast Tomosynthesis, Lunit INSIGHT DBT, was CE marked under Europe’s latest Medical Device Regulation (MDR) in February 2023. Following the CE marked under the MDR, Lunit INSIGHT DBT also received FDA 510(k) Clearance in November 2023. It is currently commercially available in Europe and the United States.

3. World’s first RCT (Randomized Controlled Trial)

The world’s first RCT published in Radiology shows that Lunit INSIGHT CXR increased the detection of actionable lung nodules on chest radiographs in real-world health screening settings. 

The study was performed in a prospective, randomized controlled setting. Health checkup participants were randomized to either the AI group (radiologists with AI) or the non-AI group (radiologists without AI) for chest radiograph evaluation. 

Results showed that using AI-CAD improved the detection rate of both Lung-RADS category 4 nodules and malignant lung nodules in the chest radiographs without increasing false positives.

▶︎ Read the publication: https://pubs.rsna.org/doi/10.1148/radiol.221894

4. Agreements with Governments around the world 

Kingdom of Saudi Arabia: Lunit has actively participated in the ‘Saudi Vision 2030’ Healthcare Transformation Project, with our AI solutions selected for evaluation and clinical integration at Seha Virtual Hospital (SVH). Following collaboration with SVH, Lunit INSIGHT MMG, an AI Solution for mammography, will be supplied to Dr. Sulaiman Al Habib Medical Group, Middle East’s Largest Healthcare Provider, for the next three years. 

Lunit has also been involved in the ‘Saudi Vision 2030’ Healthcare Sandbox, initiated by the Saudi Arabian Ministry of Health. As part of the Sandbox, Lunit signed a MOU with SVH and will provide AI solutions to SVH and approximately 150 connected hospitals. Under the contract, five major hospitals across the Kingdom will deploy Lunit INSIGHT CXR, our AI solution for Chest X-rays.

Singapore: Lunit INSIGHT CXR is now integrated into Singapore's public healthcare system through our new collaboration with NTT DATA. This partnership involves Lunit, NTT DATA, Synapxe, SingHealth, and other esteemed collaborators, with support from Singapore's Ministry of Health and Smart Nation Singapore.

Australia: Lunit has recently progressed to stage 2 of the BreastScreen NSW (BSNSW) Machine Reading Solution Project, a key part of the national BreastScreen Australia Program. During the upcoming Stage 2, Lunit INSIGHT MMG will undergo prospective validation with evaluations of Lunit's recently FDA-cleared Lunit INSIGHT DBT.

5. AI Solutions has been included in Healthcare Reimbursement

FujiFilm's CXR-AID, powered by Lunit INSIGHT CXR, has been officially included in Japanese health insurance reimbursement as a facility management fee. Japanese hospitals and medical institutions can now provide enhanced diagnostic services from the government.

In Korea, Lunit INSIGHT CXR has been approved for innovative medical technology by MOHW and has begun ‘Entering Health Insurance’. It is expected that the fee will be applied from the first quarter of 2024, giving momentum to our business in Korea.

6. Lunit’s 10th Anniversary - The greatest is yet to come

Beginning as a small company founded in 2013 by six engineers, the company has evolved into a team of more than 300 dedicated Lunithians who work to conquer cancer through AI. Our software is used daily in more than 2,500 hospitals in 48 countries around the world. However, Lunit's greatest is yet to come, and we are excited to grow with you to create a healthier and more innovative future.

7. Publications featuring Lunit SCOPE IO in the Journal of Clinical Oncology, npj Precision Oncology, and more

Download

In the second study using Lunit SCOPE IO for quantitative immune phenotyping to be published in JCO, our research team demonstrated the power of AI-driven immune phenotyping in a phase III trial. This study successfully showcased the efficacy of immunotherapy + chemotherapy for NSCLC patients with EGFR or ALK mutations. 

The study was presented in an oral presentation at ESMO 2023. Other notable publications include a study demonstrating the utility of our AI software as a reference for sTIL scoring in breast cancer assessment, published in npj breast cancer. Another study used Lunit SCOPE IO for accurate prognosis prediction in stage II-II colon cancer, published in npj precision Oncology.

8. Active presence in major conferences such as ASCO, AACR, SITC, and more

Throughout the year, we presented 38 groundbreaking studies at major oncology conferences, including ASCO, AACR, SITC, ESMO, and more. These poster presentations demonstrate our commitment to exploring the most clinically impactful uses of Lunit SCOPE AI and kindle new thinking and opportunities with pharma, biotech, academic, and industry leaders—many of them currently working with Lunit. The studies highlight various applications and validations of Lunit SCOPE in multiple cancer types and treatment settings.

9. Research collaboration analyzing clinical trial data and the use of an immunotherapy drug

Download

This year, our collaborative research continued to grow with leading medical institutions such as MD Anderson and Japan’s largest oncology practice, National Cancer Center Hospital East.  One research project involved analyzing Immunohistochemistry and H&E tissue slide data from various clinical trials, including NCCHE's molecular profiling projects such as SCRUM-Japan MONSTAR-SCREEN. Another project involved analyzing the use of Merck Keytruda (pembrolizumab) and quantitative immune phenotype across multiple cancer types. 

10. Clinical use of Lunit SCOPE PD-L1 analysis through Integration into Guardant Health test

Download

In partnership with Guardant Health, Lunit SCOPE PD-L1 was integrated into the Guardant360 TissueNext™ PD-L1 test for non-small cell lung cancer (NSCLC). The newly integrated algorithm aimed to enable Guardant to offer augmented biomarker assessment for NSCLC patients through AI-based quantification of tissue samples, using a scoring system generated by our AI. The enhanced test was designed to support pathologists in diagnosing PD-L1 status with higher accuracy and efficiency. Through our AI software, the test showed improved detection of PD-L1 by more than 20 percent compared to manual pathologist interpretation in the most challenging cases in NSCLC.

▶︎ Interested in delving deeper into business or our AI solution? Contact us now!